


ABSTRACT

The invention provides a novel class of cyclic oximes of Formula I:



wherein A, X, Y, Z, W, R₁, R₂, R₃ and n are as described in the summary of the invention;
useful in the treatment or prevention of diseases or disorders mediated by lymphocyte
interactions, particularly diseases associated with EDG receptor mediated signal transduction.